Abstract：【Objective】To explore the impact of blood lipid levels before the first chemotherapy on liver dysfunction after chemotherapy in patients with esophageal cancer.【Methods】Eighty-four esophageal cancer patients with normal liver function undergoing their first chemotherapy were divided into two groups based on pre-chemotherapy blood lipid levels: the abnormal lipid group (n=49) and the normal lipid group (n=35). The occurrence of liver dysfunction after chemotherapy was compared between the two groups. Logistic regression analysis was used to assess the impact of pre-chemotherapy blood lipid levels on post-chemotherapy liver dysfunction.【Results】Before chemotherapy, there were no significant differences in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) levels between the abnormal and normal lipid groups (P>0.05). Patients in the abnormal lipid group had higher levels of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) (P<0.05), and lower level of high-density lipoprotein cholesterol (HDL-C) compared to the normal lipid group (P<0.05). The occurrence rate of liver dysfunction after chemotherapy was 44.90%(22/49) in the abnormal lipid group, which was higher than that in the normal lipid group at 20.00%(7/35) (P<0.05).After chemotherapy, patients with liver dysfunction had higher serum TC, TG, and LDL-C levels, and lower HDL-C level compared to those with normal liver function (P<0.05). Serum TC, TG, LDL-C, and HDL-C were independent risk factors for liver dysfunction after chemotherapy in patients with esophageal cancer (P<0.05).【Conclusion】Patients with esophageal cancer who have abnormal blood lipid parameters before the first chemotherapy are at a higher risk of developing liver dysfunction afterwards. Clinicians should strengthen preventive measures.
[1] GONZALEZ R S, RAZA A, PROPST R, et al. Recent advances in digestive tract tumors: updates from the 5th edition of the world health organization "Blue Book"[J].Arch Pathol Lab Med,2021, 145(5):607-626.
[2] 王东琴,霍浩然,张欣,等. 腹腔镜消化道肿瘤根治性术及腔内热灌注化疗联合术后生物免疫治疗对消化道肿瘤患者安全性和生活质量的影响[J].临床和实验医学杂志,2021,20(12):1283-1287.
[3] MAHLMANN J C, WIRTH T C, HARTLEBEN B, et al. Chemotherapy and hepatic steatosis: impact on postoperative morbidity and survival after liver resection for colorectal liver metastases[J].Visc Med,2021, 37(3):198-205.
[4] FU S C, HE K X, TIAN C X, et al. Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells[J].Nat Commun,2020, 11(1):438-447.
[5] 周晓军,樊祥山. 解读2010年消化系统肿瘤WHO分类(Ⅰ)[J].临床与实验病理学杂志,2011,27(4):341-346.
[6] 吴焕林. 高血压与高脂血症(中西医结合慢性病防治指导与自我管理丛书)[M]. 北京:人民卫生出版社, 2013:59.
[7] 于乐成,茅益民,陈成伟.药物性肝损伤诊治指南[J].中国病毒病杂志,2015,10(5):321-341.
[8] DONATI F, CIONI D, GUARINO S, et al. Chemotherapy-induced liver injury in patients with colorectal liver metastases: findings from MR imaging[J].Diagnostics (Basel),2022, 12(4):867-875.
[9] 夏坤健,邓林林,王琳.乳腺癌化学治疗致肝损伤预测模型的构建及其评价[J].上海交通大学学报(医学版),2022,42(4):502-509.
[10] 赵轶婷,董文文,崔猛胜.胆固醇及其代谢产物在乳腺癌中的研究进展[J].中国当代医药,2021,28(22): 37-41.
[11] HEEREN J, SCHEJA L. Metabolic-associated fatty liver disease and lipoprotein metabolism[J].Mol Metab,2021, 50(3):1238-1246.
[12] KAHLEOVA H, PETERSEN K F, SHULMAN G I, et al. Effect of a low-fat vegan diet on body weight, insulin sensitivity, postprandial metabolism, and intramyocellular and hepatocellular lipid levels in overweight adults: a randomized clinical trial[J].JAMA Netw Open,2020, 3(11):454-463.
[13] 李晓爽,马飞,孙晓莹,等.血脂异常对乳腺癌患者首次化疗后肝功能的影响[J].天津医药,2021,49(10):1081-1085.
[14] 姚乐,高金宝,张志斌,等.晚期食管癌患者一线化疗前基线营养状态对化疗疗效、不良反应和患者生存期的影响观察[J].贵州医药,2021,45(11):1709-1710.
[15] 李晓爽,马飞,孙晓莹,等.血脂异常对乳腺癌患者首次化疗后肝功能的影响[J].天津医药,2021,49(10):1081-1085.
2024, Vol. 41 
